SIM
VNDA icon

Strategic Investment Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Strategic Investment Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-10,078
Closed -$144K – 133
2014
Q4 		$144K Buy
+10,078
New +$119K 0.04% 84

Other funds holding VNDA

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Strategic Investment Management's VNDA Position: Q1 2015 in Review

Strategic Investment Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2015, closing a stake of 10,078 shares — an estimated $144K sold.

Strategic Investment Management first reported a position in VNDA in Q4 2014 and held it in 1 quarter. The position peaked at $144K in Q4 2014. 110 funds tracked by Wall St. Rank hold VNDA as of Q1 2015.

  • Strategic Investment Management reported no remaining Vanda Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Strategic Investment Management sold 10,078 Vanda Pharmaceuticals shares in Q1 2015, an estimated $144K.
  • Strategic Investment Management first reported a position in Vanda Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • Strategic Investment Management's Vanda Pharmaceuticals position peaked at $144K in Q4 2014.
  • 110 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2015.

Based on Strategic Investment Management's 13F filing for Q1 2015, filed 14 May 2015.